Form 4: Iovance Biotherapeutics Executive Reports Stock Transaction
Insider Transaction (Form 4)
Raj K. Puri, Chief Regulatory Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on September 8, 2026.
Summary
- Option exercise/conversion: acquired 9,766 Common Stock on September 8, 2026; holds 260,842 after (Direct).
- Tax/exercise-price withholding: disposed of 4,478 Common Stock at $8.70 ($38,959) on September 8, 2026; holds 256,364 after (Direct).
- Option exercise/conversion: disposed of 9,766 Restricted Stock Units on September 8, 2026; holds 58,599 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Raj K. Puri — Officer (Chief Regulatory Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Option exercise/conversion | Common Stock | 9,766 | — | — | 260,842 |
| 2026-09-08 | Tax/exercise-price withholding | Common Stock | 4,478 | $9 | $39.0K | 256,364 |
| 2026-09-08 | Option exercise/conversion | Restricted Stock Units | 9,766 | — | — | 58,599 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Option exercise/conversion (9,766 shares) |
| 2026-09-08 | Tax/exercise-price withholding (4,478 shares) |
| 2026-09-08 | Option exercise/conversion (9,766 shares) |
Keywords
insider transaction, Form 4, IOVA, IOVANCE BIOTHERAPEUTICS, INC., neutral, Raj K. Puri
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.